Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Cidofovir Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 known ✓ | P11362 | 4/20 | 0.98 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.95 |
| ▸ | TYMP | P19971 | 3/20 | 0.49 |
| ▸ | HPRT1 | P00492 | 7/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | NT5E | P21589 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cidofovir Anhydrous SCHEMBL2468382 | 1.00 | FGFR1 (0.98) | FGFR1SLC22A6TYMPHPRT1CYP3A4 | |
| Cidofovir Anhydrous SCHEMBL27629017 | 1.00 | FGFR1 (0.98) | FGFR1SLC22A6TYMPHPRT1CYP3A4 | |
| Cidofovir Anhydrous SCHEMBL1389452 | 0.99 | FGFR1 (1.00) | FGFR1SLC22A6TYMPHPRT1CYP3A4 | |
| Cidofovir Anhydrous SCHEMBL3948 | 0.99 | FGFR1 (1.00) | FGFR1SLC22A6TYMPHPRT1CYP3A4 | |
| Cidofovir Anhydrous SCHEMBL14682730 | 0.99 | FGFR1 (1.00) | FGFR1SLC22A6TYMPHPRT1CYP3A4 | |
| Cidofovir Anhydrous SCHEMBL151807 | 0.99 | FGFR1 (1.00) | FGFR1SLC22A6TYMPHPRT1CYP3A4 | |
| Cidofovir Anhydrous SCHEMBL2946566 | 0.98 | SLC22A6 (1.00) | FGFR1SLC22A6TYMPHPRT1CYP3A4 | |
| Cidofovir Anhydrous SCHEMBL2946561 | 0.98 | SLC22A6 (1.00) | FGFR1SLC22A6TYMPHPRT1CYP3A4 | |
| Cidofovir Anhydrous SCHEMBL20770422 | 0.98 | FGFR1 (0.98) | FGFR1SLC22A6TYMPHPRT1CYP3A4 | |
| Cidofovir Anhydrous SCHEMBL12988503 | 0.98 | SLC22A6 (1.00) | FGFR1SLC22A6TYMPHPRT1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12485131-B2 | Formulations of brincidofovir | EMERGENT BIODEFENSE OPERATIONS LANSING LLC (US) | 2025-12-02 | — | — | US | disclosed |
| EP-3474822-B1 | FORMULATIONS OF BRINCIDOFOVIR | EMERGENT BIODEFENSE OPERATIONS LANSING LLC (US) | 2025-07-09 | — | — | EP | disclosed |
| CN-119139329-A | Preparation of brinzdofovir | 应急生物防御行动兰辛有限责任公司 | 2024-12-17 | — | — | CN | disclosed |
| CN-118416082-A | Preparation of brinzdofovir | 应急生物防御行动兰辛有限责任公司 | 2024-08-02 | — | — | CN | disclosed |
| CN-117795096-A | Methods, compositions and kits for preparing sequencing libraries | 吉复生物科技有限公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-117624239-A | Cytidine derivatives and process for preparing same | 中国人民解放军军事科学院军事医学研究院 | 2024-03-01 | — | — | CN | disclosed |
| EP-4295853-A2 | FORMULATIONS OF BRINCIDOFOVIR | Emergent BioDefense Operations Lansing LLC (US) | 2023-12-27 | — | — | EP | disclosed |
| US-20230210873-A1 | FORMULATIONS OF BRINCIDOFOVIR | WELLS FARGO BANK, NATIONAL ASSOCIATION | 2023-07-06 | — | — | US | disclosed |
| US-20230172961-A1 | THERAPEUTICS FOR COVID-19 | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-06-08 | — | — | US | disclosed |
| CN-114569547-A | Preparation of brinciclovir | 奇默里克斯公司 | 2022-06-03 | — | — | CN | disclosed |
| EP-2371369-A1 | EGFR inhibitor and antiviral agent for simultaneous, separate or sequential use in the treatment and/or prevention and/or palliation of cancer | Institut Gustave Roussy (IGR) (FR) | 2011-10-05 | — | — | EP | disclosed |
| US-8017135-B1 | Lipid-drug conjugates for local therapy of eye diseases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-09-13 | — | — | US | disclosed |
| WO-2011053812-A1 | METHODS OF TREATING VIRAL ASSOCIATED DISEASES | CHIMERIX, INC. (US) | 2011-05-05 | — | — | WO | disclosed |
| WO-2011003194-A1 | ONCOLYTIC VIRUSES AND METHODS FOR TREATING NEOPLASTIC DISORDERS | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2011-01-13 | — | — | WO | disclosed |
| US-20100137341-A1 | DNA POLYMERASE INHIBITORS COMPOSITION AND METHODS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2010-06-03 | — | — | US | disclosed |
| EP-2155209-A1 | DNA POLYMERASE INHIBITORS COMPOSITION AND METHODS | The Trustees of the University of Pennsylvania (US) | 2010-02-24 | — | — | EP | disclosed |
| US-20090192077-A1 | North-2'deoxy -methanocarbathymidines as antiviral agents for treatment of kaposi's sarcoma-associated herpes virus | HEALTH AND HUMAN SERVICES, THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF | 2009-07-30 | — | — | US | disclosed |
| US-20090181931-A1 | ANTIVIRAL ACTIVITY OF CIDOFOVIR AGAINST ONCOLYTIC VIRUSES | ONCOLYS BIOPHARMA, INC. (JP) | 2009-07-16 | — | — | US | disclosed |
| WO-2008134033-A1 | DNA POLYMERASE INHIBITORS COMPOSITION AND METHODS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2008-11-06 | — | — | WO | disclosed |
| WO-2006113204-A2 | THYMIDINE DERIVATIVES FOR TREATMEMT OF KAPOSI'S SARCOMA | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210873-A1 | FORMULATIONS OF BRINCIDOFOVIR | SAMHD1, UGT2B7, HPRT1 | FGFR1 1658/4885SLC22A6 523/4885TYMP 15/4885 |
| US-20230172961-A1 | THERAPEUTICS FOR COVID-19 | ACE, ACE2, PNP | FGFR1 4184/4885SLC22A6 3129/4885TYMP 29/4885 |
| US-20090181931-A1 | ANTIVIRAL ACTIVITY OF CIDOFOVIR AGAINST ONCOLYTIC VIRUSES | TYMP, DCTD, SAMHD1 | FGFR1 3451/4885SLC22A6 2800/4885TYMP 1/4885 |
| US-12485131-B2 | Formulations of brincidofovir | SAMHD1, UGT2B7, HPRT1 | FGFR1 1658/4885SLC22A6 523/4885TYMP 15/4885 |
| US-20090192077-A1 | North-2'deoxy -methanocarbathymidines as antiviral agents for treatment of kaposi's sarcoma-associated herpes virus | SAMHD1, TK2, DCTD | FGFR1 4700/4885SLC22A6 797/4885TYMP 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.